Efficacy and Safety of Triple-Combination Clindamycin Phosphate 1.2%/Benzoyl Peroxide 3.1%/Adapalene 0.15% Polymeric Gel in Pediatric Participants with Acne

Main Article Content

Lawrence F Eichenfield
University of California, San Diego School of Medicine

Linda Stein Gold
Henry Ford Health System

Leon Kircik
Icahn School of Medicine at Mount Sinai Department of Dermatology

William P Werschler
Elson S. Floyd College of Medicine, Washing State University

Kenneth Beer
University of Miami Miller School of Medicine

Zoe D Draelos
Dermatology Consulting Services, PLLC

Emil A Tanghetti
Center for Dermatology and Laser Surgery

Kim Papp
K Papp Clinical Research and Probity Medical Research

Hilary Baldwin
Acne Treatment and Research Center

Edward Lain
Austin Institute for Clinical Research

Neil Sadick
Weill Cornell Medical College

Eric Guenin
Ortho Dermatologics

Keywords

acne, efficacy, safety, triple combination, clindamycin, benzoyl peroxide, adapalene

References

1. Yentzer BA, et al. Cutis. 2010;86:94–99

2. Nguyen CM, et al. Clin Cosm Invest Dermatol. 2016;9:383–392

3. Tan JK, et al. J Cutan Med Surg. 2008;12(5):235–242

4. Hester C, et al. Pediatr Dermatol. 2016;33(1):49–55

5. Kraft J and Freiman A. CMAJ. 2011;183(7):E430–E435

6. Tanghetti EA, et al. J Drugs Dermatol. 2006;5(3):256–261

7. Yentzer BA, et al. Cutis. 2010;86:103–108

8. Stein Gold L, et al. Am J Clin Dermatol. 2022;23:93–104

Article Sidebar

Poster PDF
Published
Nov 16, 2022
DOI https://doi.org/10.25251/skin.6.supp.85

Article Details

How to Cite
[1]
Eichenfield, L.F., Stein Gold, L., Kircik, L., Werschler, W.P., Beer, K., Draelos, Z.D., Tanghetti, E.A., Papp, K., Baldwin, H., Lain, E., Sadick, N. and Guenin, E. 2022. Efficacy and Safety of Triple-Combination Clindamycin Phosphate 1.2%/Benzoyl Peroxide 3.1%/Adapalene 0.15% Polymeric Gel in Pediatric Participants with Acne. SKIN The Journal of Cutaneous Medicine. 6, 6 (Nov. 2022), s85. DOI:https://doi.org/10.25251/skin.6.supp.85.
Issue
Vol. 6 No. 6 (2022): November Issue & Poster Presentations from FC22 Dermatology Conference®
Section
Acne & Rosacea
Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

All authors retain copyright in their articles. All articles published open access allowing for immediate free access to the work and permitting any user to read, download, copy, distribute, print, search, or link to the full texts of articles, crawl them for indexing, pass them as data to software or use them for any other lawful purpose. Permitted reuse is defined by  the following user license:
 

Creative Commons Attribution (CC BY): lets others distribute and copy the article, to create extracts, abstracts, and other revised versions, adaptations or derivative works of or from an article (such as a translation), to include in a collective work (such as an anthology), to text or data mine the article, even for commercial purposes, as long as they credit the author(s), do not represent the author as endorsing their adaptation of the article, and do not modify the article in such a way as to damage the author's honor or reputation. 

Authors retain copyright in their work and license the publisher to publish the content. The publisher is the National Society for Cutaneous Medicine, with production and publishing support provided by OJS, Open Journal Systems,see https://pkp.sfu.ca/ojs/.

Prior to January 2022, authors transferred copyright to the National Society for Cutaneous Medicine. However, all articles are freely available to anyone in the world. There are no subscription fees, page charges, or article processing charges.

Most read articles by the same author(s)

1 2 3 4 5 6 7 8 9 10 > >>